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for differentiating childhood tuberculosis (TB), and for establishing an enhanced survey of
adverse reactions of Bacilli Calmette-Guerin vaccination in Taiwan. Future development and
evaluation of new diagnostics should be prioritized in strengthening the management of child-
hood TB.
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Tuberculosis (TB) causes 9 million cases annually, of which
at least 15e20% cases occur in children.1,2 In 2010, the TB
incidence rate was 58 per million in the population and the
absolute numbers of new TB cases was 13,237 in Taiwan. Of
these new cases, 0.6% occur in children (0e14 years).3
Clinical presentations of childhood TB are different from
adult cases. They tend to have shorter and more frequent
transition from primary infection to obvious disease and
a higher proportion of cases develop noncavitary pulmonary
TB or extrapulmonary TB. It is assumed that most children
respond well to anti-TB treatment and have less sideboratory of Mycobacteriology,
nters for Disease Control,
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transmission, however, they may later contribute to an
epidemic. Detection of childhood TB is based on epidemi-
ological, clinical and X-ray findings. Due to the difficulties
in obtaining microbiological diagnosis and less infectious-
ness, children generally receive lower priority in a TB
control program. Bacilli Calmette-Guerin (BCG) immuniza-
tion is recommend to preventing serious miliary TB and
disseminated TB in children.5 In Taiwan, neonatal BCG
vaccination has been included in the National Immunization
Program since 1965.
Accurate diagnosis of childhood TB was hindered by
improper specimen and inadequate diagnostics. In general,
only a few children cases are confirmed using standard
bacteriological laboratory tests since children are less likely
to expectorate, and the bacterial load is lower in young
children. To overcome the obstacle of laboratory diagnosis,
the reference laboratory of mycobacteriology at Taiwan
Centers for Disease Control (Taiwan CDC) has set up several& Formosan Medical Association. All rights reserved.
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for diagnosing suspected childhood TB cases and for
confirming BCG-related adverse effects. Nevertheless,
conventional bacteriological tests including acid-fast-stain
microscopy, cultivation, nonmolecular-based identification
and drug susceptibility testing (DST) are suggested. Taiwan
CDC implemented policies regarding childhood TB cases
without lung involvement in children aged under 5 years old
since 2008, and in cases in the age group <15 from 2010 to
2011 whereby it is mandatory to submit their specimens for
further identification.
Methods
Types of specimen for bacteriological diagnosis include
expectorated sputum, induced sputum, nasopharyngeal
aspirate, gastric washing, stool, string test, lymph node
aspiration, pus, cerebrospinal fluid, bone and biopsy samples
etc. Various molecular diagnostics including real-time poly-
merase chain reaction (PCR), multiplex PCR, line-probe
assays, genotyping and gene sequencing have been applied
in our routine services. A real-time PCR was designed using
an IS6110 probe for Mycobacterium tuberculosis complex
detection.6,7 Indeterminate real-time PCR results are
further confirmed by IS6110 nested PCR.8,9 Multiplex PCR
was performed for differentiating M. tuberculosis complex,
M. bovis and M. bovis-BCG, and PCR products are further
analyzed using sequencing.10 Two line-probe assay kits (Hain
Lifescience GmbH, Nehren, Germany) are used according to
manufacturer’s suggestions: (1) GenoType MTBC for differ-
entiating BCG from other M. tuberculosis complex species;
(2) GenoType MTBDRplus for detecting M. tuberculosis
complex and its rifampicin and isoniazid resistance.11
Besides, genotyping method, mainly spoligotyping, is adop-
ted for differentiating M. bovis, M. bovis-BCG and M.
tuberculosis complex.12 DNA sequencing of 16S13 or pncA
gene14 can be used for mycobacteria identification and M.
bovis family differentiation, respectively.
Diagnosis of TB and BCG infection
Children with symptoms suggestive of pulmonary TB cases
and those with no symptoms but with identifiable TB contact
and with normal immune status are suggested to have rapid
TB diagnosis and/or genotyping for identifying infectious
sources. In 2007, we confirmed a mothereinfant trans-
mission case according to matched genotyping results of the
mother’s M. tuberculosis isolate and an intestinal specimen
from the 90-day-old infant.15 In 2009, Taiwan CDC imple-
mented a rapid diagnosis policy on multidrug-resistant TB
(MDR-TB) cases using the GenoType MTBDRplus assay
directly on clinical sputa of high risk populations, such as
retreated cases (relapse, treatment after failure and
default) and contacts of MDR-TB cases. For example, we
timely identified a family MDR-TB cluster within 3 working
days, and two young girls were able to be promptly cared
in our MDR-TB treatment consortium without waiting for
results of lengthy bacterial culture and DST.
We have established the laboratory diagnosis program for
identifying of BCG adverse effects since 2003. During
2005e2007, we received 19 clinical specimens from 19childhood TB cases and found 15 (78.9%) cases were infec-
ted with M. bovis-BCG.16 The estimated incidence of BCG
osteitis/osteomyelitis was 12.9 per million vaccinations in
Taiwan during 2005e2007 and that of world was 1e700.17 In
2008, Taiwan CDC initiated a laboratory-based comprehen-
sive BCG adverse events following immunization surveil-
lance program to monitor local adverse events and severe
complications. During 2008e2009, 53 childhood TB cases
without lung involvement were notified, and specimens of
41 (77.4%) cases were submitted for differential diagnosis.
Of the 41 cases, 24 (58.5%) were infected M. bovis-BCG
(unpublished data). Therefore, contact investigation of the
index TB case could be halted if rapid bacteriological
clarification was applied. Nevertheless, the causes and risk
factors of side effects are merited to further identification.
Summary
Rapid and differential diagnosis of childhood TB using
modern molecular techniques is crucial for prompt treat-
ment and appropriate management. Nevertheless, spec-
imen collection remains a major obstacle in the diagnosis of
children TB cases. Improved sputum and multiple anatom-
ical site specimen collection can improve sensitivity and
shorten the time of diagnosis.18 Advances in the diagnosis
of TB have included molecular methods including in-house
PCR, integrated real-time PCR, sequencing and genotyp-
ing, etc. Along with clinical evaluation, we have success-
fully employed molecular techniques for differentiating
childhood TB and for establishing an enhanced survey of
adverse reactions of BCG. The development and evaluation
of new diagnostics should be prioritized in strengthening
laboratory diagnosis of childhood TB.
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